TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7537913
Drug: Novel approaches
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel approaches (differentiating agents, anti-angiogenesis factors, antitumor antigen-based therapy, growth factor receptor/ligand therapy, gene therapy)
Study: 2030804
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg o.d. (n = 62)
Study: 2030804
Drug: Captopril/nifedipine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril/nifedipine combination
Study: 6786635
Drug: Fried karela
Normalized name: peptone,dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fried karela fruits consumed as a daily supplement
Study: 26842665
Drug: Whey Protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey Protein (WP) 24 g
Study: 26842665
Drug: Maltodextrin (MD)
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin (MD) 24 g
Study: 17435957
Drug: Soy milk
Normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy milk (72 mg isoflavones/day)
Study: 17435957
Drug: Cow's milk
Normalized name: Cow's milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow's milk and isoflavone supplement (70 mg isoflavones/day)
Study: 17435957
Drug: Cow's milk
Normalized name: Cow's milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cow's milk and placebo supplement (control)
Study: 11896339
Drug: IV fluid
Normalized name: IV fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV fluid replacement (500 mL of HES)
Study: 8576296
Drug: 3.5 mg
Normalized name: niacin 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mg intravenous 4‐trans‐hydroxyglibenclamide (M1)
Study: 8576296
Drug: 3.5 mg
Normalized name: niacin 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mg intravenous 3‐cis‐hydroxyglibenclamide (M2)
Study: 8576296
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of intravenous and oral administration of glyburide
Study: 2198414
Drug: Dapsone 100
Normalized name: dapsone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 100 mg daily, non-supervised for 3 years
Study: 2198414
Drug: RMP 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMP 900 mg supervised, once weekly, 8 doses
Study: 2198414
Drug: RMP 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMP 600 mg, once monthly, supervised, 6 doses with dapsone 100 mg daily unsupervised
Study: 2198414
Drug: RMP 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMP 600 mg together with dapsone 100 mg daily, supervised for 6 days
Study: 30289444
Drug: Original-dose ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original-dose ring (VCV, 182 mg; MK-2048, 30 mg)
Study: 28275807
Drug: Semiconductor laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semiconductor laser therapy combined with botulinum toxin A type injection (50 U injected into masseteric and temporal muscles, 5 injections at different sites on each side, treatment course of 2 weeks)
Study: 22301766
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA) and 2 g α-linolenic acid (ALA)
Study: 15185464
Drug: Equivalence trials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivalence trials in cardiovascular medicine
Study: 15185464
Drug: Non-inferiority trials
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-inferiority trials in cardiovascular medicine
Study: 12006420
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 microg twice daily)
Study: 2571469
Drug: Bethanechol, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bethanechol, 10 mg subcutaneously
Study: 2571469
Drug: Midazolam, 5
Normalized name: Midazolam, 5 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam, 5 mg intramuscularly
Study: 773581
Drug: Diphenhydramine (DPH)
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine (DPH) 25 mg every 4 hr for four doses
Study: 30859862
Drug: HMB-FA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB-FA (3 g/day; n=14)
Study: 30859862
Drug: HMB-Ca (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMB-Ca (3 g/day; n=15)
Study: 30859862
Drug: Placebo (cornstarch,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cornstarch, 3 g/day; n=15)
Study: 21332331
Drug: Silymarin 140
Normalized name: silymarin 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin 140 mg 3 times daily
Study: 16047465
Drug: Colesevelam HCl
Normalized name: colesevelam HCl
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam HCl 2.3 g/day
Study: 16047465
Drug: Colesevelam HCl
Normalized name: colesevelam HCl
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam HCl 3.8 g/day
Study: 12019592
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (received a 30-minute feedback on physical capacity and individual exercise prescription and counseling)
Study: 10155357
Drug: CFC preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFC preparations
Study: 10155357
Drug: Salbutamol and
Normalized name: salbutamol and budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol and CFC preparations
Study: 1911606
Drug: Placebo sprays
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sprays
Study: 24364108
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control group 2)
Study: 12622760
Drug: 4.0 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 g/day mesalazine
Study: 12622760
Drug: 2.4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g/day mesalazine
Study: 10676721
Drug: Calcitriol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.25 microg/d) plus calcium carbonate (500 mg/d of elemental calcium)
Study: 9345358
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy + Wertheim‐Meigs + radiotherapy
Study: 27512927
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg daily for 6 months
Study: 25203576
Drug: High-pitch ultra-low-dose
Normalized name: coal tar pitch volatiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-pitch ultra-low-dose CT
Study: 19020244
Drug: Lower injection
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower injection rate protocol: 20 mL of gadopentetate dimeglumine at 2 mL/s, 8 mL of gadopentetate dimeglumine at 1 mL/s, and 20 mL of saline solution at 1 mL/s.
Study: 19020244
Drug: Higher injection
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher injection rate protocol: 20 mL of gadopentetate dimeglumine at 1.2 mL/s, 8 mL of gadopentetate dimeglumine at 0.7 mL/s, and 20 mL of saline solution at 0.7 mL/s.
Study: 16392777
Drug: Three-day treatment
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day treatment with trimethoprim
Study: 16392777
Drug: Five-day treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-day treatment with trimethoprim
Study: 3931596
Drug: 5% Albumin
Normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% Albumin added to potassium crystalloid solution
Study: 3931596
Drug: Standard potassium
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard potassium crystalloid solution
Study: 27314118
Drug: Both EC
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both EC and IC implants
Study: 14727272
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% with a basal rate of 4 mL/h and a 6 mL patient-controlled bolus available each hour (4/6 group, n = 12)
Study: 20675620
Drug: Testosterone supplementation
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone supplementation (100 mg intramuscular every 2 weeks for 26 weeks)
Study: 12102473
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with cyclosporine (CSA) and methotrexate (MTX) plus prednisone (PDN) (group B)
Study: 3040923
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy
Study: 2737235
Drug: Neostigmine 0.5
Normalized name: neostigmine 0.5 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.5 mg s.c. followed by metoclopramide 10 mg i.v.
Study: 2737235
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg i.v.
Study: 2737235
Drug: Neostigmine 0.5
Normalized name: neostigmine 0.5 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 0.5 mg s.c.
Study: 27203508
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (fluticasone furoate 100 μg and vilanterol 25 μg)
Study: 30165984
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (100 μg)
Study: 30165984
Drug: Vilanterol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilanterol (25 μg)
Study: 12581974
Drug: Glucocorticoid (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid (20 mg/d for 10 d, gradually decreased afterwards) + vitamin B + coenzyme Q10
Study: 24582567
Drug: 3000 mg
Normalized name: talc 3000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 mg resveratrol daily for 8 weeks
Study: 20089104
Drug: FCH PETCT
Normalized name: piperazine
DrugBank: Piperazine (DB00592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FCH PETCT imaging at 15 min after injection
Study: 20089104
Drug: FCH PETCT
Normalized name: piperazine
DrugBank: Piperazine (DB00592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FCH PETCT imaging at 60 min after injection
Study: 18059587
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein plus carbohydrate beverage (10 g protein and 21 g fructose)
Study: 18059587
Drug: Carbohydrate-only beverage
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-only beverage (21 g fructose and 10 g maltodextran)
Study: 16525941
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Bisoprolol + Enalapril)
Study: 793524
Drug: UV irradiation
Normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV irradiation with 1% CCT ointment
Study: 793524
Drug: UV irradiation
Normalized name: Influenza B virus B/Brisbane/60/2008 antigen (UV, formaldehyde inactivated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV irradiation with ointment
Study: 793524
Drug: 1% CCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% CCT ointment and UV irradiation
Study: 793524
Drug: High-concentration (6%)
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-concentration (6%) tar ointment without UV irradiation
Study: 28406788
Drug: Disease-modifying agents
Normalized name: LIPID MODIFYING AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying agents (DMAs) with varying characteristics including dosage type, efficacy, relapse risk, and side effects.
Study: 23994379
Drug: Schwarz measles
Normalized name: measles virus vaccine live, attenuated Schwarz strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz measles vaccine (SW)
Study: 23994379
Drug: Edmonston-Zagreb measles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edmonston-Zagreb measles vaccine (EZ)
Study: 2877594
Drug: Succinylcholine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (1.5 mg/kg)
Study: 8436517
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose rate 0.73 Gy.h‐1
Study: 8436517
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose rate 0.38 Gy.h‐1
Study: 8436517
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose rate group (0.73 Gy.h‐1)
Study: 3453705
Drug: Ribomunyl (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribomunyl (active medicine)
Study: 20370962
Drug: Various treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatment monotherapies, combinations, or augmentation strategies (specifics not detailed)
Study: 15906588
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg once daily for 14 days
Study: 15906588
Drug: Solifenacin 10
Normalized name: solifenacin 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 10 mg once daily for 14 days
Study: 16005564
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg and 10 mg
Study: 12654606
Drug: Tirofiban administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban administered in the emergency room
Study: 12654606
Drug: Tirofiban administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban administered later in the catheterization laboratory
Study: 12654606
Drug: Tirofiban (early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban (early administration)
Study: 10473830
Drug: Surgery after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery after finishing chemotherapy and locoregional radiotherapy (group B 1)
Study: 10473830
Drug: Surgery after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery after receiving only full-dose locoregional radiotherapy (group B 2)
Study: 1717776
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of benazepril and cadralazine
Study: 1316404
Drug: Benazepril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (10 mg)
Study: 6355533
Drug: Verapamil hydrochloride,
Normalized name: Verapamil Hydrochloride, 80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil hydrochloride, 80 mg four times daily
Study: 6852987
Drug: Atenolol 200
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 200 mg
Study: 4003239
Drug: Atenolol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (all doses combined)
Study: 27135916
Drug: Probiotic capsules
Normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsules
Study: 22424822
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg twice daily for 12 weeks)
Study: 18754270
Drug: simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 80 mg + ezetimibe 10 mg
Study: 18754270
Drug: simvastatin 80
Normalized name: simvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin 80 mg + placebo
Study: 11273847
Drug: Soy+ protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy+ protein (80 mg aglycone isoflavones, 42 g/d)
Study: 11273847
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein (42 g/d)
Study: 11273847
Drug: Soy- protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy- protein (trace amounts of isoflavones, 42 g/d)
Study: 8296708
Drug: ANF (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANF (2 micrograms/kg intravenously) plus furosemide (1.3 mg/kg intravenously)
Study: 8296708
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus furosemide (1.3 mg/kg intravenously)
Study: 3190990
Drug: Bupivacaine HCl
Normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine HCl 1.4 mg kg‐1 by i.m. injection after no premedication
Study: 20233525
Drug: Closed circuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed circuit (CC)
Study: 20233525
Drug: Semi-closed circuit
Normalized name: Semi-Daonil
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-closed circuit (SCC) at 4 l/min
Study: 20233525
Drug: Semi-closed circuit
Normalized name: Semi-Daonil
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-closed circuit (SCC) at 2 l/min
Study: 15801245
Drug: Desloratadine-pseudoephedrine, 5/240-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine-pseudoephedrine, 5/240-mg tablets
Study: 16913264
Drug: Desloratadine, 5
Normalized name: Desloratadine, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine, 5 mg
Study: 15801245
Drug: Pseudoephedrine, 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine, 240 mg
Study: 16179595
Drug: L-NMMA
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA
Study: 2194055
Drug: Fosfomycin (FOM)
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin (FOM) dry syrup at 60 mg/kg body weight for 5 days
Study: 2194055
Drug: Fosfomycin (FOM)
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosfomycin (FOM) dry syrup
Study: 27044326
Drug: Vilanterol (VI)
Normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vilanterol (VI) 6.25 μg and VI 12.5 μg
Study: 27044326
Drug: Vilanterol (VI)
Normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vilanterol (VI) 6.25 μg, VI 12.5 μg, VI 25 μg
Study: 19933173
Drug: Open lung
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open lung ventilation (recruitment manoeuvres, tidal volume 6 ml kg(‐1) predicted body weight, and 12 cm H(2)O PEEP)
Study: 19933173
Drug: Conventional ventilation
Normalized name: VENTILATOR FILTER,THERMOFLO #6000S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ventilation (no recruitment manoeuvres, tidal volume 10 ml kg(‐1) predicted body weight, and zero end‐expiratory pressure)
Study: 6104615
Drug: Triazolam 0.5
Normalized name: triazolam 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.5 mg for 3 weeks
Study: 27839965
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) gel therapy (2mL/cm2 of ulcers), performed weekly for 4 weeks
Study: 31948604
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) gel therapy
Study: 24379229
Drug: Control PN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control PN (10% glucose, 2.8 g/kg per day protein/lipid)
Study: 20861716
Drug: Naproxen alone
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen alone (250 mg/d, n = 42)
Study: 19503811
Drug: Comparator drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator drug
Study: 27702715
Drug: Boiled water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boiled water (BW treatment)
Study: 11489700
Drug: Doxazosin 2
Normalized name: doxazosin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 2 mg
Study: 15860390
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of doxazosin
Study: 11973182
Drug: S(+)‐ketamine 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine 1 mg/kg alone (Group K)
Study: 11973182
Drug: S(+)‐ketamine 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine 1 mg/kg with clonidine 1 microg/kg (Group C1)
Study: 11973182
Drug: S(+)‐ketamine 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: S(+)‐ketamine 1 mg/kg with clonidine 2 microg/kg (Group C2)
Study: 7674231
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (CysA) 5 mg/kg daily
Study: 7674231
Drug: Hydroxychloroquine (OH-Chlor)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (OH-Chlor) 6 mg/kg daily
Study: 28837443
Drug: cathodal transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: cathodal transcranial direct current stimulation (c‐tDCS) to unaffected primary motor cortex (PMC) plus conventional occupational therapy (OT)
Study: 21159035
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose (200 mg intravenously daily on days 1-4)
Study: 21159035
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose (200 mg intravenously daily on days 1-4) + recombinant human erythropoietin (10,000E)
Study: 19214375
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day etidronate (Group E)
Study: 19214375
Drug: 2.5 mg/day
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/day risedronate (Group R)
Study: 14731170
Drug: HAART treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART treatment
Study: 14731170
Drug: Non-HAART treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-HAART treatment (antimicrobial therapy)
Study: 2808786
Drug: 12% ammonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12% ammonium lactate lotion
Study: 6336928
Drug: 5% lactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lactic acid lotion